+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Artificial Intelligence in Diabetes Management Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 183 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904643
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Artificial intelligence in diabetes management is reshaping healthcare delivery, offering organizations a pathway to enhance digital health infrastructure, optimize operational efficiency, and improve patient outcomes. Executive leaders are leveraging AI-driven insights and integrated digital platforms to address rising demand for proactive, coordinated chronic disease care.

Market Snapshot: Artificial Intelligence in Diabetes Management

In 2024, the artificial intelligence in diabetes management market attains a value of USD 1 billion, supported by a robust 31.57% compound annual growth rate. Healthcare leaders are accelerating adoption of advanced machine learning and secure cloud-based solutions, creating agile, data-focused care environments. Sophisticated digital infrastructure and continuous patient monitoring are enabling healthcare organizations to refine workflows, ensure seamless care coordination, and promote timely information exchange across teams. As regulatory expectations evolve and continuous care gains priority, these digital capabilities are essential to meeting the sector’s demands.

Scope & Segmentation: Comprehensive Market Breakdown

  • Device Types: Integration spans standard blood glucose meters, continuous glucose monitoring systems, and a variety of insulin pumps including patch, tubed, and closed-loop models, facilitating tailored care delivery across diverse patient profiles.
  • Technology Enablers: The market is driven by cloud-based solutions, machine learning-powered decision support systems, predictive analytics, and mobile applications. These technological foundations are central to connecting providers with actionable patient data and supporting self-management strategies.
  • End Users: Tools are designed for specialty diabetes centers, general clinics, hospitals, research entities, and home healthcare teams. Segment-specific customization ensures all care delivery settings can achieve efficient, high-quality patient management.
  • Deployment Models: Organizations can select from public cloud, private cloud, hybrid deployments, or on-premise installations, which offers flexibility in meeting local IT, risk management, and privacy demands.
  • Diabetes Types: Solutions address gestational diabetes, all stages of type 1 diabetes, and the full range of type 2 diabetes, providing scalable management options aligned with varying patient group requirements and supporting wider population health initiatives.
  • Core Components: Wearable biosensors, digital monitoring devices, and secure software applications enable seamless integration of clinical data and operational workflows while maintaining high levels of data privacy.
  • Geographic Coverage: The market encompasses the Americas, Europe, Middle East and Africa, and Asia-Pacific regions. Adoption is led by key markets such as the United States, Germany, China, India, and Brazil, with implementation priorities guided by local policy, regulatory frameworks, and regional innovation.
  • Featured Companies: Industry participants include Medtronic plc, Abbott Laboratories, Dexcom Inc., F. Hoffmann-La Roche Ltd, Insulet Corporation, Tandem Diabetes Care Inc., Teladoc Health Inc., Omada Health Inc., Bigfoot Biomedical Inc., and Glooko Inc., all advancing AI-enabled diabetes management solutions.

Key Takeaways for Senior Decision-Makers

  • Artificial intelligence in diabetes management empowers real-time risk detection, alerting clinicians to potential complications and supporting prompt, preventative interventions.
  • Integrating diverse data sources across operational and clinical systems fosters improved collaboration and transparency, streamlining care delivery across multidisciplinary teams.
  • Flexible deployment options allow healthcare organizations to align technology infrastructure with evolving compliance, privacy, and regulatory requirements while pursuing ongoing digital modernization.
  • Strategic partnerships between healthcare providers and technology vendors are instrumental in ensuring effective digital transformation and maximizing solution impact throughout care networks.
  • Machine learning-driven analytics enable the design of agile, personalized intervention and prevention plans tailored to organizational and patient needs.

Tariff Impact: U.S. Trade Policy and Market Strategy

Recent U.S. tariffs on medical and digital health technology imports are prompting healthcare organizations to reevaluate sourcing strategies. By emphasizing domestic supply chains and hybrid or on-premise digital infrastructure, organizations gain greater regulatory flexibility and resilience. This approach helps stabilize costs, support compliance obligations, and safeguard ongoing technology implementation.

Methodology & Data Sources

The findings in this report are based on direct input from clinicians, digital health executives, and regulatory experts active in the diabetes care domain. Data are independently validated and supplemented by reliable market intelligence, ensuring informed strategic planning for industry stakeholders.

Why This Report Matters

  • Supports senior leadership with a practical blueprint for adopting artificial intelligence in diabetes management, guiding decision-making from initial strategy through implementation.
  • Delivers comprehensive segmentation and regulatory analysis, informing risk management and supporting market entry or expansion efforts.
  • Offers a forward-looking perspective on digital health adoption, helping leaders anticipate emerging trends and maintain a competitive market stance.

Conclusion

Investing in artificial intelligence within diabetes management enables organizations to establish secure, integrated, and scalable care processes, positioning them for continued innovation and resilience within the evolving global digital health landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Integration of continuous glucose monitoring data with AI predictive algorithms to personalize insulin dosing based on real-time lifestyle patterns
5.2. Deployment of machine learning models in wearable devices for early detection of hypoglycemic events among high-risk diabetic patients
5.3. Use of natural language processing in virtual health assistants to provide tailored dietary and medication advice for diabetic individuals
5.4. Development of federated learning frameworks to train AI diabetes management models across multiple institutions while preserving patient data privacy
5.5. Adoption of AI-driven smartphone applications for automated meal recognition and insulin bolus recommendations using computer vision techniques
5.6. Collaboration between pharma companies and tech firms to validate AI-enabled closed-loop insulin delivery systems in large-scale clinical trials
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Artificial Intelligence in Diabetes Management Market, by Device Type
8.1. Blood Glucose Meter
8.1.1. Non Invasive Bg Meter
8.1.2. Smbg
8.2. Closed Loop System
8.2.1. Fully Closed Loop
8.2.2. Hybrid Closed Loop
8.3. Continuous Glucose Monitor
8.3.1. Intermittently Scanned Cgm
8.3.2. Real Time Cgm
8.4. Insulin Pump
8.4.1. Patch Pump
8.4.2. Tubed Pump
9. Artificial Intelligence in Diabetes Management Market, by Technology
9.1. Cloud Computing
9.1.1. Private Cloud
9.1.2. Public Cloud
9.2. Decision Support Systems
9.2.1. Alert Generation
9.2.2. Dose Recommendation
9.3. Machine Learning
9.3.1. Reinforcement Learning
9.3.2. Supervised Learning
9.3.3. Unsupervised Learning
9.4. Mobile Applications
9.4.1. Android
9.4.2. Ios
9.5. Predictive Analytics
9.5.1. Glucose Trend Prediction
9.5.2. Risk Prediction
10. Artificial Intelligence in Diabetes Management Market, by End User
10.1. Clinic
10.1.1. Diabetes Center
10.1.2. General Clinic
10.2. Home Care
10.2.1. Remote Monitoring
10.2.2. Self Monitoring
10.3. Hospital
10.3.1. Inpatient
10.3.2. Outpatient
10.4. Research Institute
10.4.1. Academic
10.4.2. Private
11. Artificial Intelligence in Diabetes Management Market, by Deployment Mode
11.1. Cloud Based
11.1.1. Hybrid Cloud
11.1.2. Public Cloud
11.2. On Premise
11.2.1. Edge Computing
11.2.2. Server Based
12. Artificial Intelligence in Diabetes Management Market, by Type
12.1. Gestational
12.1.1. First Trimester
12.1.2. Second Trimester
12.1.3. Third Trimester
12.2. Type 1
12.2.1. Adult Onset
12.2.2. Juvenile Onset
12.3. Type 2
12.3.1. Insulin Dependent
12.3.2. Non Insulin Dependent
13. Artificial Intelligence in Diabetes Management Market, by Component
13.1. Hardware
13.1.1. Pumps
13.1.2. Sensors
13.1.3. Wearable Devices
13.2. Software
13.2.1. Algorithms
13.2.2. Data Management
13.2.3. User Interface
14. Artificial Intelligence in Diabetes Management Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Artificial Intelligence in Diabetes Management Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Artificial Intelligence in Diabetes Management Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Medtronic plc
17.3.2. Abbott Laboratories
17.3.3. Dexcom, Inc.
17.3.4. F. Hoffmann-La Roche Ltd
17.3.5. Insulet Corporation
17.3.6. Tandem Diabetes Care, Inc.
17.3.7. Teladoc Health, Inc.
17.3.8. Omada Health, Inc.
17.3.9. Bigfoot Biomedical, Inc.
17.3.10. Glooko Inc.

Companies Mentioned

The companies profiled in this Artificial Intelligence in Diabetes Management market report include:
  • Medtronic plc
  • Abbott Laboratories
  • Dexcom, Inc.
  • F. Hoffmann-La Roche Ltd
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • Teladoc Health, Inc.
  • Omada Health, Inc.
  • Bigfoot Biomedical, Inc.
  • Glooko Inc.

Table Information